|Bid||57.00 x 1000|
|Ask||65.00 x 1800|
|Day's Range||62.97 - 63.98|
|52 Week Range||31.51 - 64.00|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||26.28|
|Earnings Date||Nov 02, 2020 - Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.60|
The drugmaker wants a judgment in favor of programs that would let it help cover Medicare patients’ copays for an expensive cardiovascular drug.
Alaska’s Department of Revenue materially increased investments in Gilead Sciences and Eli Lilly stock in the third quarter. It also bought more Wells Fargo and sold Bank of America stock.
The diagnostic giant is now processing 200,000 tests a day for the coronavirus. But with a number of new tests and a business running clinical trials, LabCorp is preparing for whatever normal will be. Plus: the president’s Covid-19 drugs
On Friday, data on Gilead Sciences’ Remdesivir showed that that it cut recovery time in patients by five days. This comes as Johnson & Johnson have signed a deal with the European Union to supply the countries with 400 million doses of its vaccine. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
• The Trump administration is working on a new $1.8 trillion economic stimulus package, which would be its highest offer yet in its negotiations with Democratic leaders in Congress. Treasury Secretary was expected to discuss the new spending plan with House Speaker (D., Calif.) on Friday, according to a report in The Wall Street Journal. • The World Health Organization said Friday the 338,779 new Covid-19 infections in the previous 24 hours was a new one-day record.
Gilead Sciences said on Thursday that it has agreed to supply Europe with up to 500,000 courses of remdesivir, as the region looks to boost its stockpile of the antiviral drug amid a surge in COVID-19 cases. The Commission said all participating countries can now place their orders to procure Veklury — the brand name for remdesivir — directly. Gilead (GILD) said it would begin fulfilling orders from Oct. 12.
In 2020, many drug stocks have behaved like pot stocks did in 2018. Investors have paid huge premiums on sales for even the promise of a novel coronavirus treatment or vaccine. But if you’re looking for value, consider Pfizer (NYSE:PFE). You can still buy PFE stock at a reasonable price. Source: Manuel Esteban / Shutterstock.com Pfizer was trading at $37/share early on Oct. 8. That’s a market cap of $203 billion, based on 2019 sales of $51.75 billion. But the price-to-earnings ratio is just 14.5 and the 38 cent per share dividend still yields 4.1%, at a time when the 30-year government bond trades at 1.5%. How is this possible? Blame a long history of underperformance, the efforts to improve that performance, and a preference for more speculative issues.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer’s Covid-19 Play Pfizer is the senior partner in a Covid-19 vaccine effort built on technology from BioNTech (NASDAQ:BNTX) of Germany. Investors seeking a profit on that play have been piling into BioNTech, which had 2019 sales of $109 million but entered trade Oct. 8 at $88/share, a market cap of $21 billion. Analysts say the combination, along with Moderna (NASDAQ:MRNA), are leading the race. While the market will be worth billions, the price is likely to be controlled by governments. Pfizer is the manufacturing partner, with what CEO Albert Bourla, a veterinarian by training, calls an “open checkbook.” Even before Phase 3 trials are done, the company has produced hundreds of thousands of doses of the BioNTech vaccine. 7 Innovative Stocks Pushing Our World Ahead Bourla says his company is “moving at the speed of science.” He has acted as a public face for the effort, seeking to assure consumers the result will be something safe and effective. He is caught between a president who wants to rush emergency use authorizations and a public that’s increasingly skeptical of all vaccines. In addition to the vaccine, Pfizer has begun Phase 1 studies of a treatment for Covid-19, an antiviral that will combine with Remdesivir from Gilead Sciences (NASDAQ:GILD), which Trump has been taking. Pfizer says the combination has proven potent in pre-human studies. Beyond the Coronavirus What makes Pfizer interesting lies beyond COVID, including work on other vaccines, on immunology, and on rare diseases. The company also has cash. It had $22.7 billion of cash on its balance sheet at the end of June. It recently paid $200 million for a 9.9% stake in a Chinese cancer drug company, CStone. Pfizer’s best-known vaccine is Prevnar, for pneumonia, which had sales of $5.85 billion last year. The company recently told analysts it has three more vaccines in development, whose sales could equal that figure by the end of the decade. Pfizer’s best-known drug right now is Xeljanz, an immunosuppressant (called a JAK inhibitor) for which it now has four indications, including arthritis. Xeljanz has the second-largest ad budget in the industry, recording sales of $2.24 billion last year. The Bottom Line on PFE Stock Since becoming CEO, Bourla has sought to pull Pfizer away from its “patent cliff.” Drugs like Viagra and Lipitor have lost patent protection, and are being spun out along with UpJohn from Mylan (NYSE:MYL) into a new company called Viatris. The pandemic forced a delay in that spinoff, so if you’re an income investor you can still get in by buying Pfizer. Selling off aging profit centers, however, puts the main company dividend, which costs $2.1 billion per quarter, into jeopardy. Thus, the stock hasn’t moved much. Pfizer’s current guidance is that 2020 free cash flow will come to $10 billion to $11 billion, cutting the dividend and indicating a yield of 3.6%. But board members like former FDA Commissioner Scott Gottlieb and investment banker Ronald Blaylock have been buying Pfizer lately. You might want to join them. On the date of publication, Dana Blankenhorn did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. Dana Blankenhorn has been a financial and technology journalist since 1978. He is the author of the environmental thriller Bridget O’Flynn and the Bear, available at the Amazon Kindle store. Write him at email@example.com or follow him on Twitter at @danablankenhorn. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG America’s #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Could Tiny “Super” Battery Kill Big Tech? The post Pfizer Is a Value Play in the Covid-19 Frenzy appeared first on InvestorPlace.
A new study in the New England Journal of Medicine confirmed remedsivir’s positive effect of Covid-19 patients. The stock is up in Friday trading.
It has been a year of two halves for Gilead Sciences (GILD). Following the pandemic’s onset, the pharma heavyweight was initially one of the main beneficiaries. Hopes were high Gilead’s experimental Covid-19 antiviral drug remdesivir will play its part in combating COVID-19, and shares dutifully took off.But since April’s yearly highs, Gilead has faced a series of headwinds which have stunted its market performance.Disappointing earnings, a CRL (complete response letter) from the FDA for rheumatoid arthritis (RA) treatment filgotinib, and concerns regarding remdesivir’s commercial potential, are among the reasons why shares have swung into the red in 2020.Now remdesivir is back in the headlines again, after it was announced Trump is being treated with the drug, since being diagnosed with COVID-19.Remdesivir has been given emergency use authorization (EUA) by the FDA for the treatment of hospitalized COVID-19 patients and patients with moderate symptoms. The biotech submitted an NDA (new drug application) for the treatment in August based on results of a study overseen by the National Institute of Allergy and Infectious Diseases (NIAID).Although the treatment didn't show any significant evidence of a survival benefit, in the NIAID study remdesivir meaningfully reduced the amount of time COVID-19 patients spent in the hospital. Most patients who took the treatment recuperated after 11 days or less vs the 15 days it took for the placebo group.After scouring the latest data available from the study, Raymond James analyst Steven Seedhouse believes the new data does not significantly change what is already widely known.The 5-star analyst said, “The updated data continue to suggest RDV provides only incremental benefit to some hospitalized patients but no clear mortality benefit. Recall the original corresponding NEJM publication for this trial pointed to a potential (but not yet stat sig) mortality benefit at day 14 that appeared driven really only by patients with baseline ordinal score of 5 (hospitalized, requiring any supplemental oxygen).”As a result, Seedhouse keeps a Market Perform (i.e. Hold) on GILD shares but does not provide a fixed price target. (To watch Seedhouse’s track record, click here)Overall, opinions differ on Wall Street regarding Gilead’s potential trajectory, leaning slightly to the bullish side. Based on 9 Buys, 10 Holds, and 2 Sells, the stock has a Moderate Buy consensus rating. A clearer picture emerges where the price target is concerned, as on average, the analysts expect shares to add 26.5% over the next 12 months. (See GILD stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
|Upgrade||Baird: Neutral to Outperform||4/17/2020|
|Maintains||Wells Fargo: to Overweight||3/20/2020|
|Maintains||Wells Fargo: to Overweight||12/20/2019|
|Maintains||Wells Fargo: to Outperform||11/5/2019|
|Downgrade||Longbow Research: Buy to Neutral||4/17/2019|
|Maintains||Baird: Outperform to Outperform||6/19/2018|
Full Time Employees: 6,605
Diodes Incorporated, together with its subsidiaries, designs, manufactures, and supplies application-specific standard products in the discrete, logic, and analog and mixed-signal semiconductor markets in Asia, North America, and Europe. It primarily focuses on low pin count semiconductor devices with one or more active or passive components. The company offers discrete semiconductor products, such as performance Schottky rectifiers and diodes; Zener and performance Zener diodes, including tight tolerance and low operating current type; standard, fast, super-fast, and ultra-fast recovery rectifiers; bridge rectifiers; switching diodes; small signal bipolar and pre-biased transistors; MOSFETs; thyristor surge protection devices; and transient voltage suppressors. It also provides analog products comprising power management devices consisting of AC-DC and DC-DC converters, USB power switches, and low dropout and linear voltage regulators; linear devices, such as operational amplifiers and comparators, current monitors, voltage references, and reset generators; LED lighting drivers; audio amplifiers; and sensor products, including hall-effect sensors and motor drivers. In addition, the company offers standard logic products comprising low-voltage complementary metalÂoxideÂsemiconductor (CMOS) and high-speed CMOS devices; ultra-low power CMOS logic products and analog switches; multichip products and co-packaged discrete, analog, and mixed-signal silicon in miniature packages; silicon and silicon epitaxial wafers; and crystals and oscillators. It sells its products to the consumer electronics, computing, communications, industrial, and automotive markets through direct sales and marketing personnel, independent sales representatives, and distributors. Diodes Incorporated was founded in 1959 and is headquartered in Plano, Texas.